Elanco Animal Health Enters Material Definitive Agreement

TL;DR

Elanco just signed a big deal, could affect finances.

AI Summary

Elanco Animal Health Inc. entered into a material definitive agreement on July 3, 2024, related to a direct financial obligation. The company, headquartered in Greenfield, Indiana, filed an 8-K report detailing this event. Specific details of the agreement, including the nature of the financial obligation and any associated dollar amounts, are not fully disclosed in the provided text but are indicated as material.

Why It Matters

This filing indicates a significant financial commitment or obligation for Elanco Animal Health, which could impact its financial standing and future operations.

Risk Assessment

Risk Level: medium — The filing indicates a material definitive agreement and a direct financial obligation, suggesting potential financial risks or opportunities that are not fully detailed.

Key Players & Entities

• Elanco Animal Health Inc. (company) — Registrant
• July 3, 2024 (date) — Date of Earliest Event Reported
• Greenfield, Indiana (location) — Principal Executive Offices
• 877-352-6261 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $400 million — of such indebtedness equals or exceeds $400 million (subject to certain exceptions)). The A

Filing Documents

• tm2418797d1_8k.htm (8-K) — 28KB
• tm2418797d1_ex10-1.htm (EX-10.1) — 1628KB
• 0001104659-24-077840.txt ( ) — 2179KB
• elan-20240703.xsd (EX-101.SCH) — 3KB
• elan-20240703_lab.xml (EX-101.LAB) — 33KB
• elan-20240703_pre.xml (EX-101.PRE) — 22KB
• tm2418797d1_8k_htm.xml (XML) — 3KB

01 Entry Into a Material

Item 1.01 Entry Into a Material Definitive Agreement. On July 3, 2024, Elanco Animal Health Incorporated (the "Company") entered into Amendment No. 2 to its Credit Agreement (as amended, the "Credit Agreement"), by and among the Company, as borrower, Elanco US Inc., as co-borrower, the subsidiary loan parties party thereto, the revolving facility lenders and the issuing banks party thereto, certain exiting revolving facility lenders, JPMorgan Chase Bank, N.A., as revolving facility agent, and Goldman Sachs Bank USA, as term facility agent, collateral agent and security trustee (the "Amendment No. 2"), relating to its senior secured first lien revolving credit facility (the "Revolving Credit Facility"). The Amendment No. 2 extended the maturity date for the Revolving Credit Facility from August 1, 2025 to July 3, 2029 (subject to, if earlier, a springing maturity of 91 days prior to the maturity date of certain long-term indebtedness of the Company and its subsidiaries if, on such date, the aggregate principal amount of such indebtedness equals or exceeds $400 million (subject to certain exceptions)). The Amendment No. 2 also made other amendments to certain other covenants and terms. The foregoing description does not purport to be complete and is qualified in its entirety by reference to the Amendment No. 2 filed as Exhibit 10.1 to this Current Report on Form 8-K, which is incorporated herein by reference. Item2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Amendment No. 2, dated as of July 3, 2024, to the Credit Agreement, dated as of August 1, 2020, by and among Elanco Animal Health Incorporated, as borrower, Elanco US Inc., as co-borrower, the subsidiary loan parties party thereto, the lenders and issuing banks party thereto from time to time, Goldman Sachs Bank USA, as term facility agent, collateral agent and security trustee, and JPMorgan Chase Bank, N.A., as revolving facility agent. 104.1 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Elanco Animal Health Incorporated Date: July 3, 2024 By: /s/ Todd Young Name: Todd Young Title: Executive Vice President and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR